Honest answer: most people feel nothing acute from TUDCA. It's not a stim, not a depressant, not euphoric, not sedating. The drug is organ-protective and the benefits are biochemical (ALT/AST normalization) and statistical (reduced apoptosis over time) rather than subjective.

What some users report:

• Mild "less bloated" / improved digestion after fatty meals — plausible via improved bile flow, particularly in users with low-grade biliary sludge, post-cholecystectomy malabsorption, or hypochlorhydria-driven fat malabsorption. The 192-report community dataset has "gut improvement" as the #2 reported effect (15 mentions), so a real signal exists in a subset.
• Subtle "energy" / less fatigue — community-reported (16 mentions). Mechanistically the TGR5-mitochondrial pathway could plausibly cause this; could also be confounded with simultaneously starting other supplements (TUDCA is rarely taken in isolation).
• No effect at all — also very common. Many users report taking 500 mg for months without noticing anything subjective; their value comes from the ALT/AST normalization on bloodwork or the peace-of-mind during AAS cycles.

What you should NOT expect:

• Acute cognitive enhancement
• Mood lift
• Sleep change
• Workout performance change
• Anything stimulant-like or sedative-like

Onset of measurable effect:

• Bloodwork (ALT/AST): 4-8 weeks at 500-750 mg/day for meaningful trend
• Subjective digestion changes (if any): days to 2 weeks
• Neuroprotective effects: invisible at the individual level; relevant only at population-RCT scale

For Dylan specifically: Without an active hepatic stressor, expect to feel essentially nothing. This is normal and not a failure. The reason to take it is statistical — buffering occasional Tylenol use, alcohol exposure during nights out, eventual modafinil load — not for an acute feel.

• Tolerance buildup: none documented. Bile-acid pool replacement and ER-stress chaperone effects don't have an obvious receptor-downregulation mechanism. The TGR5/FXR signaling could theoretically downregulate with chronic high doses but no clinical signal of this exists in PBC long-term users.
• Recommended cycle: None mandatory. Use indefinitely if there's an indication. For supplement-cabinet "buffer" use, deploy only on stressor weeks — not because of tolerance, but because daily use without indication is low-yield and wastes money.
• Reset protocol: N/A. No washout needed even after months of daily use.
• What's NOT cycled: The "TUDCA cycle support" terminology is borrowed from AAS culture, where cycling refers to the AAS, not the TUDCA. TUDCA itself runs continuously during the AAS cycle + 2-4 weeks post-PCT until liver enzymes normalize.

Synergistic with

• NAC (already V4-locked, 600-1,200 mg): Strongest evidence-based pairing. NAC restores glutathione (Phase II detox); TUDCA reduces ER stress + protects mitochondria. Complementary mechanisms, both well-evidenced, both inexpensive, both safe. Used together in essentially every cycle-support protocol and in some clinical liver-disease research stacks. For Dylan: keep NAC as the daily anchor, layer TUDCA as situational.
• Milk thistle / silymarin: Common pairing but NOT mechanistically synergistic in any rigorous way. Milk thistle's evidence base is weaker than TUDCA's. If you have one of the two, TUDCA is the better-evidenced choice. Stacking both is acceptable but adds cost without much marginal benefit.
• Choline / phosphatidylcholine: Theoretically supports VLDL packaging and lipid export from liver — meaningful in NAFLD context, less so in healthy users. Mild stack rationale; not a priority.
• Taurine (already plausible in Dylan's stack): Background pairing — TUDCA contains taurine in its conjugation. Free taurine has independent benefits (cardiac, GABA-ergic, bile-acid pool support). Combining is fine; not strongly synergistic.
• Omega-3 (already V4-locked): Anti-inflammatory in liver; mild rationale for stacking in NAFLD context. Neutral-to-mildly-positive interaction.
• CoQ10: Mitochondrial support; mechanistic synergy with TGR5-mitochondrial arm of TUDCA. Modest evidence for combined use in NAFLD animal models.

Avoid stacking with

• Cholestyramine, colestipol, colesevelam (bile acid sequestrants): bind TUDCA in the gut, defeating absorption. Separate by ≥4 hours if both prescribed.
• Aluminum-containing antacids: similar binding/interference; separate by 2 hours.
• High-dose vitamin C with calcium at the same dose moment: theoretical interference; minor. Separate by 1 hour if concerned.

Neutral / safe co-administration

• All of Dylan's V4 stack supplements (Mg, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vitamin C) — no interactions known.
• Creatine — neutral.
• Caffeine — neutral.
• Modafinil — neutral / mildly positive (TUDCA could theoretically buffer the mild hepatic load of chronic modafinil; this is exactly the Dylan-specific stack rationale).
• Most peptides (BPC-157, TB-500, Semax, Selank) — neutral.
• SSRIs, SNRIs — neutral.
• Standard statins — neutral; some animal data suggests TUDCA mildly mitigates statin-induced mitochondrial side effects but no human data.

TUDCA's metabolic profile:

• Largely unaffected by CYP450 enzymes; metabolism is via bacterial deconjugation in the gut + hepatic re-conjugation
• Does NOT induce or inhibit major CYP enzymes at supplement doses
• Minimal renal excretion; mostly fecal

Clinically significant interactions:

1. Bile acid sequestrants (cholestyramine, colestipol, colesevelam) — REDUCED ABSORPTION

• Direct binding in the gut; TUDCA never reaches systemic/enterohepatic recycling. Separate dosing by ≥4 hours.

2. Aluminum-containing antacids — REDUCED ABSORPTION

• Same mechanism (chelation/binding). Separate by 2 hours.

3. Fat-soluble drug absorption — POSSIBLY MODULATED

• Bile acids influence absorption of fat-soluble vitamins (A, D, E, K) and lipophilic drugs (cyclosporine, certain antifungals). Direction of effect with TUDCA specifically is poorly characterized; at supplement doses, clinically meaningful interaction is unlikely.

4. Oral contraceptives — NEUTRAL

• No CYP3A4 induction; no documented contraceptive interaction. Unlike modafinil, TUDCA does not compromise hormonal contraception.

5. Acetaminophen — POSSIBLY HEPATOPROTECTIVE

• Animal data shows TUDCA reduces APAP-induced liver injury when co-administered. Does NOT replace NAC for actual APAP overdose, but for routine occasional therapeutic-dose APAP, TUDCA + NAC is a reasonable hepatoprotective buffer.

6. Alcohol — POSSIBLY HEPATOPROTECTIVE

• Animal data shows TUDCA reduces ethanol-induced ER stress and apoptosis. Not licensing alcohol use, but for a night-out exposure, 500 mg TUDCA pre-/post- is a reasonable buffer.

7. 17α-alkylated oral AAS (dianabol, anadrol, superdrol, winstrol, oxandrolone) — HEPATOPROTECTIVE STACK MEMBER

• Standard adjunct in cycle-support protocols. No formal RCT but mechanism, animal data, and ALT/AST normalization patterns in case literature support 500-1,000 mg/day during the cycle and 2-4 weeks post-PCT.

8. Modafinil — NEUTRAL / MILDLY HEPATOPROTECTIVE

• Modafinil has minimal hepatic toxicity but mild CYP3A4 induction and chronic dosing creates measurable metabolic load. TUDCA at 500 mg/day during chronic modafinil use is a reasonable hedge (Dylan's V5 plan use case).

TUDCA's pharmacogenomics are thinly characterized — not a CYP-substrate, so the usual CYP2D6/2C19/3A4 polymorphism story doesn't apply. The relevant gene families:

• ASBT (SLC10A2) — apical sodium-dependent bile acid transporter: Loss-of-function variants reduce ileal bile acid reabsorption. In carriers, oral TUDCA absorption could be reduced. No commercial PGx panels report this routinely; 23andMe raw data via Promethease could surface it.
• FXR (NR1H4): Variants affect bile acid receptor signaling; clinical relevance for TUDCA response is undetermined.
• TGR5 (GPBAR1): Variants influence bile-acid metabolic and inflammatory signaling. Knockout mouse studies show TUDCA's gut-barrier effect depends on TGR5 — human variants could plausibly modulate response but no clinical PGx data exists.
• MDR3 (ABCB4): Loss-of-function variants cause progressive familial intrahepatic cholestasis type 3; UDCA/TUDCA response varies by genotype. Not relevant for healthy users; relevant if a hepatology workup ever flags PFIC-3.
• UGT1A1 polymorphism (Gilbert's syndrome): Carriers (~5-10% population) have elevated indirect bilirubin baseline. TUDCA is generally well-tolerated; no specific contraindication. Useful to know baseline if running ALT/AST + bilirubin panels — Gilbert's-pattern unconjugated hyperbilirubinemia shouldn't be confused with cholestatic injury.

For Dylan: 23andMe raw data (June 2026 results window) is unlikely to surface anything actionable for TUDCA specifically. The interesting PGx targets (CYP2D6, CYP2C19, COMT, HLA-B) are more modafinil/Adderall/SJS-relevant. TUDCA decisions don't require PGx input.

Sourcing-difficulty rating: easy. No gray market, no telehealth required, no Rx needed for supplement use. The product itself is straightforward — bile acid molecule, simple identification, low counterfeit incentive.

Brand-by-brand quality:

• Nutricost 250 mg / 500 mg: Reliable generic. Often the price-leader on Amazon/iHerb.
• Double Wood 250 mg / 500 mg: Third-party tested; slightly higher price point.
• BodyBio TUDCA 250 mg: Premium brand; popular in functional medicine circles. No clinical advantage but reliable.
• Nutrabio 500 mg: Solid mid-tier brand with batch testing.

For Dylan: Order Nutricost or Double Wood 500 mg × 60 caps via iHerb (~$25). Take 500 mg AM on stressor days only. One bottle should last 3-6 months at situational use; ~$5/month effective cost.

Payment + shipping: Standard supplement retailer rails. No regulatory friction.

Baseline (before starting any chronic protocol)

• ALT, AST, GGT, alkaline phosphatase — liver enzyme panel; baseline before any "liver support" supplement so you can quantify the buffer's actual effect.
• Total + direct bilirubin — flag Gilbert's syndrome pattern early; rule out cholestatic injury at baseline.
• CBC — basic safety baseline.
• Lipid panel — bile acids modulate cholesterol metabolism; baseline lets you track any FXR-mediated lipid changes.
• Fasting glucose, HbA1c — Kars 2010 metabolic data suggests insulin-sensitivity effects; track if running chronic TUDCA.

During use (continuous chronic dosing — uncommon for Dylan)

• ALT/AST at 4-8 weeks if running for a specific liver buffer (post-AAS cycle, chronic modafinil, isotretinoin).
• Repeat liver panel quarterly for chronic users.
• Bilirubin + GGT — adds specificity if any flag appears.

Situational use (Dylan's expected pattern)

• Standard bloodwork at usual intervals (June 2026, then annually) — TUDCA at situational doses shouldn't move bloodwork meaningfully but you want clean trend lines.
• No additional monitoring required at <1 g/day intermittent dosing.

Self-tracked / subjective

• Digestion VAS (1-10, post-fatty-meal bloat) — if you're taking it partly for digestive comfort, track to calibrate whether the effect is real or placebo.
• Energy / fatigue VAS — if community-reported "energy" effect is what you're chasing, log baseline and on-dose comparisons. Expect noise.